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Abstract
Background: The clinical characteristics of Takayasu arteritis (TAK) developing in individuals older than 40 years
(TAK >40) are little-known.
Method: We retrospectively analyzed 43 patients with TAK treated at three hospitals in Japan from April 2000 to
March 2016. From medical records we collected baseline variables at diagnosis including clinical symptoms,
laboratory data, and subsequent relapses. We compared these indices in the patients with TAK onset at >40 years
of age (TAK >40) to those with TAK onset ≤40 years (TAK ≤40). Multiplex cytokine/chemokine bead assays were
performed using preserved serum supernatants from 24 patients with TAK and 40 healthy donors.
Results: Of the 43 patients, 20 had TAK >40; this group had significantly fewer instances of orthostatic hypotension (2
(10%) vs. 10 (43%), p = 0.019), carotid bruit (7 (35%) vs. 16 (70%), p = 0.034), and chest pain (0 (0%) vs. 6 (26%), p = 0.023)
compared to patients with TAK ≤40 (n = 23). The initial prednisolone dose was significantly lower in TAK >40 (median
30 mg vs. 40 mg per day, p = 0.024). Assessed by the log-rank test, the relapse-free survival rate after remission was
significantly higher in the patients with TAK >40 (p = 0.029). The interleukin 17 levels were significantly lower in patients
with TAK >40 compared to patients with TAK ≤40 and healthy donors.
Conclusion: Compared to TAK ≤40, TAK >40 could be treated by lower initial doses of prednisolone to
achieve remission, and with fewer relapses. These differences might be due to the difference of T helper 17
(Th17) activity suggested by the cytokine profiles.
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Background
Takayasu arteritis (TAK) is a type of large-vessel vasculitis
that predominantly affects young women [1]. In general,
TAK is diagnosed based on The American College of
Rheumatology (ACR) 1990 criteria for the classification of
Takayasu arteritis [2], which consist of the following six
components: (1) age at disease onset ≤40 years (TAK ≤40);
(2) claudication in the extremities; (3) decreased brachial
artery pulse; (4) difference between arms in systolic blood
pressure of 10 mmHg; (5) bruit over the subclavian arteries
or the aorta; and (6) abnormality on arteriogram. Patients
with at least three of these components are classified as
having TAK. When these ACR criteria were used in a previ-
ous study, of 63 patients of TAK, there were only 4 with
onset of TAK >40 years of age (TAK >40) [2]. In contrast,
in a French study, 32% of patients with TAK had TAK> 40
[3], which suggests that it is not rare to be diagnosed with
TAK >40 years of age.
The patient’s age at diagnosis is important in auto-
immune diseases. For example, the clinical characteristics
of patients with elderly-onset rheumatoid arthritis (RA) are
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different from those of younger patients with RA [4]. Simi-
larly, age at diagnosis is important in distinguishing TAK
from giant cell arteritis (GCA), because both TAK and
GCA are categorized as forms of large-vessel vasculitis; in
addition, the ACR 1990 criteria for the classification of
GCA [5] include the component ‘age at disease onset
≥50 years.’ The boundaries between TAK and GCA have
become increasingly blurred in the clinical aspects of these
conditions [6]. Therefore, age at diagnosis or at disease on-
set is very important.
Ohigashi et al. reported the clinical characteristics of
patients with TAK >40; these patients had significantly
more coronary artery disease and hypertension, and sig-
nificantly fewer instances of aortic regurgitation [7].
However, except for this study, little is known about the
relationship between the age of disease onset and clinical
characteristics of TAK.
Here we attempted to identify the clinical differences,
including relapse and prognosis, in patients with TAK >40
and patients with TAK ≤40. In addition, we evaluated dif-
ferences in the profile of serum cytokines and chemokines
at diagnosis between TAK >40 and TAK ≤40.
Methods
Patients and study criteria
We retrospectively analyzed all patients with TAK who
were registered and followed by the Nagasaki University
Hospital, Sasebo Chuo Hospital, and NHO Nagasaki Med-
ical Center between April 2000 and March 2016. We in-
cluded patients with diagnosis based on the ACR 1990
criteria for the classification of TAK [2]. Four patients were
excluded because detailed data were missing at diagnosis
and/or during the disease course. One patient was excluded
because she developed TAK during chemotherapy for
ovarian cancer. A final total of 43 patients were included
this study (Fig. 1). They were all newly diagnosed with TAK
and were followed up for at least 6 months. No enrolled pa-
tients fulfilled the ACR 1990 criteria for the classification of
GCA [5].
To compare the characteristics of TAK among patients
of different age at disease onset, we divided the 43 pa-
tients by age at disease onset: >40 years old (the TAK
>40 group) and ≤40 years old at disease onset (the TAK
≤40 group). None of the TAK >40 patients had history
of symptoms of TAK 40 years of age. TAK >40 fulfilled
three or more items in the ACR criteria for TAK without
the definition of onset of age. TAK ≤40 also fulfilled
three or more items, including age.
Relapse was determined by Japan College of
Rheumatology-certified rheumatologists by confirmation of
the recurrence of active disease as described [8]. The cri-
teria for relapse were the detection of a new vascular lesion
or lesions (aneurysms, stenoses or occlusions, or new ir-
regularities of the arterial wall) in arteries (aorta, innomin-
ate, subclavian, axillary, common and internal carotid,
vertebral, superior and inferior mesenteric, renal, common
iliac, or celiac axis) on angiography (including computed
tomography) in patients who had undergone angiography
before being evaluated for relapse, or at least two of the fol-
lowing: (1) new onset of carotidynia or pain over the large
vessels; (2) transient ischemic episodes not attributable to
other factors; (3) new bruit or new asymmetry in pulses or
blood pressure determination; (4) ischemic symptoms (in-
cluding new-onset claudication); and (5) fever in the ab-
sence of infection. Angiography was performed when the
patient’s attending doctor considered it necessary on the
basis of the patient’s clinical characteristics. We recruited
healthy donors (HD) from the staff of Nagasaki University.
Fig. 1 Flow diagram: 43 patients with Takayasu arteritis (TAK) were included in the study
Fukui et al. Arthritis Research & Therapy  (2016) 18:293 Page 2 of 10
Clinical and laboratory analysis
We collected baseline information at diagnosis, including
clinical characteristics and laboratory data and subsequent
relapses, by accessing the patients’ medical records. The
baseline clinical characteristics at diagnosis included age,
sex, symptoms, body mass index (BMI), history of smok-
ing, angiographic classification types, and complications
including diabetes mellitus (DM) and chronic kidney dis-
ease (CKD) (these complications influence vascular condi-
tions), inflammatory bowel diseases (IBD), and pyoderma
gangrenosum (PG) (TAK is frequently complicated with
IBD or PG).
The initial laboratory data included human leukocyte
antigen (HLA) typing, white blood cell count, hemoglobin,
platelet count, C reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), albumin (Alb), and immunoglobulin
G (IgG). Baseline information at diagnosis was collected
within 2 weeks before treatment started, except for the
HLA typing.
We analyzed the corticosteroid doses received in both
the initial treatment and on relapse in the 43 patients with
TAK who had been followed up for ≥6 months. Informa-
tion on the use of pulsed methylprednisolone and immu-
nosuppressants including methotrexate, cyclosporine, and
tacrolimus was also collected, as was information on the
use of biologics including infliximab, adalimumab, and
tocilizumab. The corticosteroid doses were calculated as
daily prednisolone equivalents. The rate of reduction in
the prednisolone dose (mg/month) was calculated using
the reduction dose during the 6 months after starting cor-
ticosteroid treatment. In particular, we subtracted the
prednisolone dose at 6 months after remission from the
initial prednisolone dose and we divided the difference by
6 months.
Multiplex cytokine/chemokine bead assays
Multiplex cytokine/chemokine bead assays were per-
formed using diluted serum supernatants and Milliplex
MAP Human Cytokine/Chemokine Panel 1 Pre-mixed
41Plex (Merck Millipore, Darmstadt, Germany) analyzed
with a Bio-Plex® MAGPIX™ Multiplex Reader (Bio-Rad,
Hercules, CA, USA) according to the manufacturers’ in-
structions. The cytokines/chemokines measured by the
Milliplex MAP Human Cytokine/Chemokine Panel 1
Pre-mixed 41Plex included vascular endothelial growth
factor (VEGF), TNF-β, TNF-α, transforming growth fac-
tor (TGF)-α, regulated and normal T cell expressed and
secreted (RANTES), platelet-derived growth factor
(PDGF)-AB/BB, PDGF-AA, macrophage inflammatory
protein (MIP)-1β, MIP-1α, myeloid dendritic cells
(MDC) (CCL22), monocyte chemotactic protein (MCP)-
3, MCP-1, IP-10, IL-17, IL-15, IL-13, IL-12 (p70), IL-12
(p40), IL-10, IL-9, IL-8, IL-7, IL-6, IL-5, IL-4, IL-3, IL-2,
IL-1ra, IL-1β, IL-1α, interferon (IFN)-γ, IFN-α2, growth-
related cytokine (GRO), granulocyte macrophage-colony
stimulating factor (GM-CSF), granulocyte-colony stimu-
lating factor (G-CSF), fractalkine, Flt-3 ligand, fibroblast
growth factor (FGF)-2, eotaxin, epidermal growth factor
(EGF), and sCD40L.
Serum obtained from patients with TAK at diagnosis
and from HD was centrifuged within 30 minutes at
1500 rpm at 4 °C for 5 minutes, and the liquid phase
serum was stored at −80 °C until use. Serum from HD
was divided into two analysis groups of HD older than
40 years (HD >40) and HD who were ≤40 years old (HD
≤40). We compared serum from HD with serum from
patients with TAK >40 and TAK ≤40. Serum was ob-
tained from HD in 2013–2015. The earliest obtained
serum from a patient at diagnosis was 2009. Multiplex
cytokine/chemokine bead assays using serum from pa-
tients and HD were performed in 2015–2016.
Statistical analysis
We compared the baseline characteristics, including
demographic data, hematologic data, serum markers,
treatments, and follow-up duration between the TAK
>40 and TAK ≤40 groups. Variables are described using
frequencies for categorical variables and with the median
and interquartile range (IQR) for quantitative variables.
We assessed the association between variables using
Fisher’s exact test for categorical variables and Wilcox-
on’s rank sum test for quantitative variables. The
relapse-free survival rate after remission was estimated
by the Kaplan-Meier method. The association between
the relapse-free survival rate and TAK >40 or TAK ≤40
was evaluated by the log-rank test. All tests were two-
sided and a p value <0.05 was considered significant.
The Steel-Dwass test was performed for comparisons of
multiplex cytokine/chemokine bead assay results in the
four groups, i.e., TAK >40, TAK ≤40, HD >40, and HD
≤40. All statistical analyses were performed using JMP
Statistical Software, ver. 11 (SAS Institute, Cary, NC,
USA) and GraphPad Prism ver. 7.0 (GraphPad Software,
San Diego, CA, USA).
Results
Baseline characteristics
The study population was 43 patients who were identi-
fied over the 16-year period. Twenty of the patients with
TAK were classified as TAK >40. Table 1 shows the
demographic, clinical and laboratory characteristics of
the TAK >40 and TAK ≤40 (n = 23) groups. Median age
in the TAK >40 and TAK ≤40 groups was 56 and
23 years, respectively. The positive rate of HLA-B52, the
rate of complications, and angiographic classification
were not significantly different between the two groups.
In contrast, the TAK >40 group had significantly lower
rates of orthostatic hypotension (2 (10%) vs. 10 (43%), p
Fukui et al. Arthritis Research & Therapy  (2016) 18:293 Page 3 of 10
= 0.019), carotid bruit (7 (35%) vs. 16 (70%), p = 0.034)
and chest pain (0 (0%) vs. 6 (26%), p = 0.023) at diagnosis
compared to the TAK ≤40 group. There were no
significant between-group differences in CRP or ESR.
Furthermore, because we could not eliminate the poten-
tial bias in the diagnosis of TAK by using the criterion
Table 1 Demographic, clinical, and laboratory characteristics of patients in the TAK >40 and TAK ≤40 groups
Variable TAK >40, n = 20 TAK ≤40, n = 23 P value
Onset age (IQR) 56 (48–62) 23 (20–28)
Female, n (%) 19 (95) 21 (91) 1.00
HLA-B52, n (%) 7 (47) , n = 15 11 (65), n = 17 0.48
BMI, kg/m2 (IQR) 21.9 (20.2–26.2) 21.2 (18.9–22.7) 0.55
Family history 1 (5) 0 (0) 0.47
Smoking 5 (25) 4 (17) 0.71
Complication, n (%)
DM 2 (10) 2 (9) 1.00
CKD 0 (0) 2 (9) 0.49
IBD 1 (5) 2 (9) 1.00
PG 1 (5) 1 (4) 1.00
Angiographic classification, n (%)
Type I 5 (25) 5 (22) 1.00
Type IIa 2 (10) 3 (13) 1.00
Type IIb 3 (15) 4 (17) 1.00
Type IV 1 (5) 0 (0) 0.47
Type V 9 (45) 11 (48) 1.00
Fever 11 (55) 14 (61) 0.76
Malaise 10 (50) 12 (52) 1.00
Headache 5 (25) 12 (52) 0.118
Dizziness 0 (0) 5 (22) 0.051
Orthostatic hypotension 2 (10) 10 (43) 0.019*
Ophthalmic symptoms 1 (5) 4 (17) 0.35
Carotid bruit 7 (35) 16 (70) 0.034*
Cervical pain 4 (20) 6 (26) 0.73
Discrepancy of blood pressure 10 (50) 11 (48) 1.00
Upper limb pain 4 (20) 9 (39) 0.20
Pulselessness 4 (20) 6 (26) 0.73
Chest pain 0 (0) 6 (26) 0.023*
Abdominal bruit 6 (30) 6 (26) 1.00
Arthralgia 5 (25) 6 (26) 1.00
Aortic valve regurgitation 5 (25) 7 (30) 0.74
WBC, ×103/μL (normal range 3.5–9.8) (IQR) 9.4 (7.1–11.7), n = 20 8.2 (6.6–10.3), n = 23 0.56
Hb, g/dL (normal range11.3–17.6) (IQR) 12.4 (10.1–13.2), n = 20 10.8 (9.4–12.0), n = 23 0.054
Plt × 104/μL, (normal range 13.0–36.9) (IQR) 29.3 (23.4–38.2), n = 20 35.1 (25.1–47.0), n = 23 0.28
CRP, mg/dL (normal range <0.14) (IQR) 4.2 (0.5–9.0), n = 20 7.0 (0.6–9.6), n = 23 0.62
ESR, mm/h, (normal range <15) (IQR) 75 (32–91), n = 18 77 (27–106), n = 17 0.74
Alb, g/dL, (normal range 3.8–5.2) (IQR) 3.7 (3.1–4.1), n = 19 3.6 (3.2–4.3), n = 21 0.95
IgG, mg/dL, (normal range 870–1700) (IQR) 1410 (1100–1670), n = 17 1660 (1190–2190), n = 22 0.33
TAK >40 Takayasu arteritis onset after age 40 years; TAK ≤40 TAK onset age 40 years or younger, BMI body mass index, DM diabetes mellitus, CKD chronic kidney
disease, IBD inflammatory bowel diseases, PG pyoderma gangrenosum, WBC white blood cell count, Hb hemoglobin, Plt platelet, CRP C reactive protein, ESR
erythrocyte sedimentation rate, Alb albumin, IgG immunoglobulin. *p < 0.05
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of age at disease onset, we extracted TAK ≤40 who ful-
filled at least three of the five criteria excluding the cri-
terion of age at disease onset from the whole TAK ≤40
group and then compared these patients with the TAK
>40 group (Table 2). In the TAK ≤40 group, 14 out of 23
patients fulfilled at least three of the five criteria exclud-
ing the criterion of age at disease onset. Patients with
TAK ≤40 who fulfilled at least three criteria excluding
the age criterion had significantly more headaches, dizzi-
ness, orthostatic hypotension, upper limb pain, chest
pain and lower hemoglobin levels compared to the TAK
>40 group; however, there were largely no differences as
compared with the data in Table 1.
Treatments
Table 3 shows the characteristics of the treatments ad-
ministered to the TAK >40 and TAK ≤40 groups. The
initial prednisolone dose was significantly lower in the
TAK >40 compared to the TAK ≤40 group (median
30 mg vs. 40 mg per day, respectively, p = 0.024). The
initial prednisolone dose per kg of body weight was also
significantly lower in the TAK >40 compared to the TAK
≤40 group (0.55 mg/kg per day vs. 0.80 mg/kg per day,
p = 0.048). There were no significant between-group dif-
ferences in the other immunosuppressants. Five patients
in the TAK ≤40 group were treated with infliximab com-
pared to none of the patients in the TAK >40 group.
There were no significant between-group differences in
the rate of reduction in the dose of prednisolone or
follow-up duration.
Outcomes
We evaluated the relapse-free survival rates in the TAK
>40 and TAK ≤40 groups, and observed that the TAK
>40 patients had significantly fewer relapses as assessed
by the log-rank test (p = 0.029) using the Kaplan-Meier
method (Fig. 2). There was no significant difference in
surgical intervention (p = 0.68), and only one patient
died, due to pancreatic cancer.
Multiplex cytokine/chemokine bead assay
We performed a multiplex cytokine/chemokine bead assay
using serum from patients with TAK >40 and patients
with TAK ≤40 obtained at diagnosis (Fig. 3). We obtained
serum from 10 patients with TAK >40, 14 patients with
TAK ≤40, 18 HD >40, and 22 HD ≤40. Median age in the
HD >40 and HD ≤ 40 groups was 46 years and 33.5 years
(IQR 43–52 and 30–38 years), respectively.
The TAK >40 group had significantly lower IL-17
compared to the TAK ≤40 and the HD >40 groups (me-
dian (IQR) 1.1 (0.2–2.5) pg/mL for TAK >40; 8.4 (2.6–
17.8) pg/mL for TAK ≤40; 5.1 (3.5–9.0) pg/mL for HD
>40; and 9.4 (6.0–39.5) for HD ≤40). In the complete
series of 24 patients with TAK, IL-6 was significantly
higher in the HD >40 and the HD ≤40 groups (median
(IQR) 26.9 (8.1–65.2) pg/mL; 23.4 (8.2–56.1) pg/mL; 0.6
(0–2.1) pg/mL; and 1.4 (0–5.5) pg/mL, respectively).
TNF-α in the TAK >40 group was significantly higher
than that in the HD >40 group (16.3 (11.2–22.1) pg/
mL for TAK >40; 13.5 (10.0–21.0) pg/mL for TAK ≤40;
7.1 (5.3–9.4) pg/mL for HD >40; and 8.3 (6.9–13.0) pg/
mL for HD ≤40 ). However, there were no significant
differences in IL-6 or TNF-α between the TAK >40 and
TAK ≤40 groups. There were no significant differences
between the TAK >40 and TAK ≤40 groups in IFN-γ, IL-
2, IL-4, IL-5, IL-8, IL-10, IL-13, GM-CSF, or RANTES
(Fig. 3). There were no further significant differences be-
tween the TAK >40 and TAK ≤40 groups in the other
cytokines/chemokines analyzed by bead assay.
Discussion
The results of the present study revealed that there are
some important clinical differences between patients with
an onset at age >40 years and those with onset at age
≤40 years. The TAK >40 group had significantly fewer in-
stances of orthostatic hypotension, carotid bruit and chest
pain at diagnosis. These clinical manifestations may be
caused by damage to the aortic arch and heart.
Individuals with TAK often experience relapses, even after
remission. It was reported that 72% of patients with TAK
experience multiple relapses within 6 months after the dose
of prednisolone is tapered to <10 mg daily [9]. It is also re-
ported that a >1.2 mg/month reduction rate in the dose of
prednisolone predicts subsequent relapse [7]. However, the
factors at diagnosis that could be used to predict subsequent
relapse of TAK following remission have not previously
been elucidated. Our present findings revealed that the TAK
>40 group experienced fewer subsequent relapses compared
to the TAK ≤40 group. This also suggests the disease char-
acteristics of TAK differ by age. In addition, it is of note in
the present study that the TAK >40 group was treated with
lower initial doses of prednisolone to achieve remission
compared to the TAK ≤40 group. We assume that each
attending physician reduced the initial prednisolone doses
in the TAK >40 group because of the risk of the adverse
effects of prednisolone, such as infections in the elderly.
Previous investigations revealed that a skewed activation
of T helper (Th)1 and Th17 pathways in patients with
TAK contributes to the systemic and vascular manifesta-
tions [10, 11]. In patients with active TAK, the expression
of IFN-γ, IL-12 and IL-17 is detected within aortic inflam-
matory infiltrates [10, 11], and the increased frequency of
IFN-γ-producing and IL-17A-producing T cells and the
increased production of Th1-related and Th17-related cy-
tokines from peripheral blood mononuclear cells (PBMCs)
has been observed [10]. Conversely, the change in Th2 or
T regulatory cell (Treg) subsets may not be determined
[11]. We thus attempted in the present study to determine
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Table 2 Demographic, clinical, and laboratory characteristics of patients in the TAK >40 and TAK ≤40 groups who fulfilled at least
three criteria, excluding the age criterion
Variable TAK >40, n = 20 TAK ≤40 who fulfilled at least three criteria,
excluding the age criterion, n = 14
P value
Onset age, years (IQR) 56 (48–62) 23 (20–29)
Female, n (%) 19 (95) 13 (93) 1.00
HLA-B52, n (%) 7 (47) , n = 15 10 (83), n = 12 0.107
BMI, kg/m2 (IQR) 21.9 (20.2–26.2) 21.2 (18.6–22.2) 0.48
Family history 1 (5) 0 (0) 1.00
Smoking 5 (25) 3 (21) 1.00
Complication, n (%)
DM 2 (10) 1 (7) 1.00
CKD 0 (0) 1 (7) 0.41
IBD 1 (5) 1 (7) 1.00
PG 1 (5) 1 (7) 1.00
Angiographic classification, n (%)
Type I 5 (25) 5 (36) 0.70
Type IIa 2 (10) 3 (21) 0.63
Type IIb 3 (15) 2 (14) 1.00
Type IV 1 (5) 0 (0) 1.00
Type V 9 (45) 4 (29) 0.48
Fever 11 (55) 10 (71) 0.48
Malaise 10 (50) 8 (57) 0.74
Headache 5 (25) 9 (64) 0.035*
Dizziness 0 (0) 4 (29) 0.022*
Orthostatic hypotension 2 (10) 8 (43) 0.006*
Ophthalmic symptoms 1 (5) 4 (29) 0.135
Carotid bruit 7 (35) 10 (71) 0.080
Cervical pain 4 (20) 4 (29) 0.69
Discrepancy in blood pressure 10 (50) 10 (71) 0.30
Upper limb pain 4 (20) 8 (57) 0.036*
Pulselessness 4 (20) 6 (43) 0.25
Chest pain 0 (0) 4 (29) 0.022*
Abdominal bruit 6 (30) 4 (29) 1.00
Arthralgia 5 (25) 3 (21) 1.00
Aortic valve regurgitation 5 (25) 7 (50) 0.16
WBC, ×103/μL (normal range 3.5–9.8) (IQR) 9.4 (7.1–11.7), n = 20 9.9 (7.1–14.3), n = 14 0.66
Hb, g/dL (normal range11.3–17.6) (IQR) 12.4 (10.1–13.2), n = 20 10.8 (8.8–11.7), n = 14 0.033*
Plt × 104/μL, (normal range 13.0–36.9) (IQR) 29.3 (23.4–38.2), n = 20 36.9 (24.2–51.7), n = 14 0.26
CRP, mg/dL (normal range <0.14) (IQR) 4.2 (0.5–9.0), n = 20 7.0 (0.9–10.0), n = 14 0.46
ESR, mm/h, (normal range <15) (IQR) 75 (32–91), n = 18 75 (50–88), n = 10 0.85
Alb, g/dL, (normal range 3.8–5.2) (IQR) 3.7 (3.1–4.1), n = 19 3.7 (3.1–4.4), n = 13 0.95
IgG, mg/dL, (normal range 870–1700) (IQR) 1410 (1100–1670), n = 17 1660 (1170–2250), n = 14 0.34
TAK >40 Takayasu arteritis onset after age 40 years; TAK ≤40 TAK onset age 40 years or younger, BMI body mass index, DM diabetes mellitus, CKD chronic kidney
disease, IBD inflammatory bowel diseases, PG pyoderma gangrenosum, WBC white blood cell count, Hb hemoglobin, Plt platelet, CRP C reactive protein, ESR
erythrocyte sedimentation rate, Alb albumin, IgG immunoglobulin. *P < 0.05
Fukui et al. Arthritis Research & Therapy  (2016) 18:293 Page 6 of 10
whether the expression of cytokines/chemokines in serum
are different in patients with TAK >40 compared to those
with TAK ≤40.
We observed that IL-6 and TNF-α were higher in pa-
tients with TAK compared to the HD, which is compatible
with previous studies using ELISA [11–13]. Our present
data suggest a new insight, i.e., that patients with TAK >40
have relatively lower IL-17 compared to those with TAK
≤40. Furthermore, this study demonstrated no differences
in IL-17 between the HD >40 and in HD ≤40 groups,
which is compatible with a previous study showing that
IL-17 does not differ between younger and older HD [14].
These observations may refute the possibility that the de-
cline of IL-17 in patients with TAK >40 simply depends
on advancing age. The present clear differences in IL-17
by age might explain the previous result, as patients with
TAK in the previous study had a relatively wide age range
at disease onset [11].
We observed no significant differences in Th1-related cy-
tokines, including IFN-γ and IL-2 and Th2-related cyto-
kines, including IL-4, IL-5, and IL-13, between the TAK
>40 and TAK ≤40 groups. Glucocorticoids are a standard
part of the treatment of TAK, and a previous study demon-
strated a decrease in Th1-derived cytokines (e.g., IFN-γ)
produced from PBMCs after glucocorticoid treatment,
whereas the production of Th17-derived cytokines (e.g., IL-
17A) was not inhibited [10]. Misra et al. also reported that
IL-17 levels do not change with different immunosuppres-
sive treatments [15]. Differences in IL-17 in the TAK >40
and TAK ≤40 groups, may suggest differences in the patho-
physiological etiology of two groups. These data suggest
that exploration of Th17 cell pathways is important to pre-
dict the disease outcome in TAK. In this regard, it is very
interesting to note that the serum levels of IL-17 were low
in our TAK >40 group, and that the clinical characteristics
were less severe in those patients compared to patients in
the TAK ≤40 group. A cross-sectional study showed a cor-
relation between serum IL-6 and TAK disease activity [11],
but this was the first report to describe an association be-
tween serum cytokines/chemokines and the outcome of
TAK that may contribute to the effect of age.
By contrast, elevated serum IL-17 in patients with
TAK compared to HD have been reported previously
[15]. In addition, Saadoun et al. report that addition of
serum from patients with active TAK to sorted CD4-
positive T cells from HD in culture medium induces sig-
nificant production of IL-17A, but only weak expression
of IL-17A in patients with active TAK was observed
within aortic inflammatory infiltrates [10]. There are
some differences between these studies and ours in the
characteristics of the patients included and the HD and
methods, including the assay and sample handling. Fur-
thermore, serum levels of cytokines and chemokines
may not necessarily reflect what is occurring in the
Table 3 Treatments and follow-up duration in the TAK >40 and TAK ≤40 groups
Variable TAK >40, n = 20 TAK ≤40, n = 23 P value
Initial dose of prednisolone, mg/day (IQR) 30 (15–40) 40 (30–45) 0.024*
Initial dose of prednisolone, mg/day (IQR) 0.55 (0.28–0.82) 0.80 (0.59–0.94) 0.048*
Pulsed methylprednisolone as an initial therapy 2 (10) 7 (30) 0.142
Methotrexate with prednisolone before relapses, n (%), mg/week (IQR) 7 (35), 8 (6–8) 9 (39), 10 (7–13) 1.00
Cyclosporine with prednisolone before relapses, n (%), mg/day (IQR) 1 (5), 150 4 (17), 160 (105–238) 0.35
Tacrolimus with prednisolone before relapses, n (%), mg/day (IQR) 1 (5), 3.0 1 (4), 0.5 1.00
Infliximab, n (%) 0 (0) 5 (22) 0.051
Adalimumab, n (%) 0 (0) 1 (4) 1.00
Tocilizumab, n (%) 1 (5) 1 (4) 1.00
Reduction rate of prednisolone dose, mg/month (IQR) 2.7 (2.3–3.0) 2.8 (2.4–2.9) 0.87
Dose of prednisolone at relapse, mg/day (IQR) 10 (8–16) 15 (11–20) 0.11
Follow-up duration, months (IQR) 70 (25–133) 55 (28–115) 0.94
TAK >40 Takayasu arteritis onset after age 40 years; TAK ≤40 TAK onset at age 40 years or younger. *P < 0.05
Fig. 2 Patients with onset of Takayasu arteritis (TAK) at age >40 years
had significantly fewer relapses as assessed by the log-rank test (p =
0.029) using the Kaplan-Meier method. TAK > 40 TAK onset after age
40 years, TAK ≤40 TAK onset age 40 years or younger
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tissues. Therefore, it is necessary to exercise caution
when considering the pathophysiology of TAK.
Our study has some limitations. First, we could not elim-
inate potential bias in the diagnosis of TAK by using the
criterion of age at disease onset. Because TAK classification
criteria include the criterion of age at disease onset
≤40 years, a prospective study is absolutely imperative to
eliminate bias in the diagnosis of TAK. To partially address
this problem, we also performed comparison of patients
with TAK ≤40 who fulfilled at least three criteria excluding
the age criterion and those with TAK >40. Second, more
cases are needed to confirm these results, particularly in
assessing the results of multiplex cytokine/chemokine bead
assays. However, this study is valuable as a hypothesis-
generating study. Third, we could not assess the T cell sub-
populations using fluorescence-activated cell sorting be-
cause this was a retrospective study. We plan to analyze T
cell subpopulations in patients with TAK >40 and TAK ≤40
in the future. Fourth, we used the ACR criteria to differenti-
ate TAK from GCA and to exclude GCA. TAK and GCA
appear more similar than different, based on clinical and
pathological findings [16]. In contrast, Michel et al. insisted
that GCA and TAK were easily definable and separable dis-
orders, even when the typical age barrier of 40 years at
Fig. 3 Results of a multiplex cytokines/chemokine bead assay using serum obtained at diagnosis from patients with Takayasu arteritis (TAK) with
disease onset over 40 years of age (TAK >40, n = 10) and age at disease onset of 40 years or younger (TAK ≤40, n = 14). Serum from healthy
donors (HD) older than 40 years (HD >40) and from HD 40 years of age or younger (HD ≤40) were compared to serum from the TAK >40 and
TAK ≤40 groups. Symbols represent individual patients or donors. Horizontal lines show the median and interquartile range. IFN-γ interferon
gamma, IL interleukin, GM-CSF granulocyte macrophage colony-stimulating factor, TNF-α tumor necrosis factor-α, RANTES regulated on activation
normal T cell expressed and secreted, N.S. not significant
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onset of disease was excluded [17]. Although all patients in
our cohort did not fulfil the ACR criteria for GCA, this
method may be insufficient to exclude it. Fifth, as TAK usu-
ally develops insidiously with non-specific symptoms, onset
at age >40 years may not correctly reflect the real onset of
the disease. However, we assume that there are no differ-
ences in the latent duration to the time that subjective
symptoms appear and physical changes are identified in
both TAK >40 and TAK ≤40. Sixth, the number of patients
in the TAK >40 group in this cohort seems high compared
to previous studies. This difference may rely on differences
in ethnicity and regions. Seventh, in multiplex cytokine/
chemokine bead assays, the duration of preservation of
serum differed. In this study, we did not find lower cytokine
and chemokine levels in serum that had been preserved for
longer periods. However, because the influence of degrad-
ation of cytokines and chemokines is unknown, we plan to
measure cytokines and chemokines in preserved serum at
various time points in our further research.
Conclusions
Patients with TAK >40 had fewer relapses after remission
compared to patients with TAK ≤40. The levels of IL-17
in the TAK >40 group at diagnosis were lower compared
to those in the TAK ≤40 group. Our findings clarified the
relationships between age, clinical characteristics, and pro-
files of cytokines and chemokines in patients with TAK.
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